Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum IMV Inc IMVIF

Healthcare Biotechnology
IMV Inc. is a Canada-based company. The Company has no business operations.

Bullboard (GREY:IMVIF)

View:
Prev ... 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 ... Next
Comment by gardyon Apr 04, 2021 1:50pm

RE:Reality Check

Ors is in no hurry to do anything. He is milking this company to the max. Problem is he is getting away with it. I met with the management of this company 10 years ago in Vancouver at my brokers ...more  
245
Discussion
Post by TexasTea20on Apr 03, 2021 8:19pm

Reality Check

Some additional thoughts on a home -boundCovid Saturday afternoon as I think more about the continued bungling of timelines, super-slow clinical progress, unreliable messaging and IMV's valuation  ...more  
372
Discussion
Comment by gardyon Apr 02, 2021 2:09pm

RE:RE:04/13/16 - Immunovaccine Names Frederic Ors Chief Executive

Ors is a spud filling up at the trough. I wish I could make over a million per annum leading a company that has not made one penny. As for management being on the board, can you say conflict of ...more  
219
Discussion
Comment by TexasTea20on Apr 01, 2021 7:04pm

RE:04/13/16 - Immunovaccine Names Frederic Ors Chief Executive

I do agree with your sentiment re Ors. The guy just doesnt resonate with investors. Needs to be demoted or moved into a different role. I really don't like it when CEO's are on the BOD. This ...more  
246
Discussion
Comment by Jthom376on Mar 31, 2021 5:41pm

RE:RE:RE:RE:I'm thinking of getting out

These missed deadlines affect everybody. Whether you're an institutional investor, or regular guy like myself, their inconsistency leaves a lasting impression. I'm here to stay but I would ...more  
258
Discussion
Comment by alexmed95on Mar 31, 2021 5:16pm

RE:RE:RE:I'm thinking of getting out

Well my problem now isn't about missed deadlines per se, more about the fact that they project "lousy" managing skills, and we, shareholders, pay dearly for it. We could have put our ...more  
215
Discussion
Comment by Hideawayon Mar 31, 2021 5:04pm

RE:RE:RE:I'm thinking of getting out

Thanks Biotech.Hope that a matter of days doen't turn into weeks. However, based on the info they gave you,I'll hold on pending news,at least for a bit.Just wondering with whom you spoke,Fred ...more  
181
Discussion
Comment by qwerty22on Mar 31, 2021 4:22pm

RE:RE:I'm thinking of getting out

It is certainly not fun, it's definitely frustrating, but my own view is nothing much changes in the investment thesis if they fail to give an update tomorrow. But everybody has to right to judge ...more  
166
Discussion
Comment by Biotech010on Mar 31, 2021 4:06pm

RE:RE:I'm thinking of getting out

i spoke with the company on this deadline. The answer I got was it was a matter of days. Getting the right people to sign in a big organization like Merck isn;t always easy :) So relax... news is ...more  
198
Discussion
Comment by Hideawayon Mar 31, 2021 3:07pm

RE:I'm thinking of getting out

Alex, I totally understand your viewpoint.In the absence of some news by AM tomorrow,I may take similar action to divest myself from this frustrating investment. Could they possibly feel we would be ...more  
213
Discussion
Post by alexmed95on Mar 31, 2021 1:58pm

I'm thinking of getting out

If after close, we don't have an update on DLBCL, they will have missed the only target they promised after changing last minute all their previous promised updates. I mean, i'm not even sure ...more  
298
Discussion
Comment by TataTradingon Mar 31, 2021 1:05pm

RE:RE:T cells induced by COVID-19 infection respond to variants

I agree. The market knows. Imagine if it didn't. We would be trading at wha???  $2.00. At the end of the day, for us investors, the news is not important. It's only the market reaction to ...more  
183
Discussion
Comment by Jthom376on Mar 31, 2021 11:58am

RE:RE:T cells induced by COVID-19 infection respond to variants

That would be nice but all I see is another missed commit as of now. It will change but their timelines are frustrating to no end
104
Discussion
Comment by Biotech010on Mar 31, 2021 11:09am

RE:T cells induced by COVID-19 infection respond to variants

very interesting! Deal with Merck about to land any day now.... and the market knows. Big buyer active!
130
Discussion
Post by TataTradingon Mar 31, 2021 10:23am

04/13/16 - Immunovaccine Names Frederic Ors Chief Executive

At the end of that day the stock was at $1.9872  or $6.36 after the 3.2 reverse split. Close to celebrating this 5 year anniversary, the stock is now at $3.92.    38.3% decline All is ...more  
253
Discussion
Prev ... 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 ... Next
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities